Treatment stratification for newly diagnosed patients fit for intensive treatment, modified after Onkopedia Guidelines for AML (www.onkopedia.com).¹ APL, acute promyelocytic leukemia excluded. ² Fit for intensive therapy, based on ECOG status and comorbidity. ³ Genetically defined subgroups according to ELN 2022. ⁴ AML MR, AML with myelodysplasia-related changes (WHO) or entities “AML with myelodysplasia-related gene mutations”, “AML with myelodysplasia-related cytogenetic abnormalities” and AML with the diagnostic qualifier “Progressed form MDS or MDS/MPN” (ICC). ⁵ t-AML, therapy-associated AML. ⁶ 7+3, therapy regimen with cytarabine (Ara-C) on 7 days, daunorubicin on 3 days. ⁷ GO, gemtuzumab ozogamicin, recommended in patients up to 70 years. ⁸ HDAC, high-dose Ara-C; IDAC, intermediate-dose Ara-C. ⁹ Low risk of recurrence: NPM1-mut without relevant MRD. High risk of recurrence: NPM1 wildtype or relevant MRD. ¹⁰ Allo HCT, allogeneic hematopoietic cell transplantation. ¹¹ This recommendation includes bZIP inframeCEBPA mutated patients. ¹² MRD monitoring recommended.